Expansion of GMP Compliant Tumor Infiltrating Lymphocytes (TILs) in Xuri bioreactor.

Stina Wickström (Karolinska Institutet), Katrin Markland (Vecura) and Bill Shingleton (Cytiva) present the Centre for Advanced Medical Products (CAMP) project towards scaleable and reliable expansion of Tumor Infiltrating Lymphocytes for clinical use against malignant melanoma. Treatment of metastatic malignant melanoma patients, who no longer responded to other types of cancer treatment, with Tumor Infiltrating Lymphocytes (TILs) and Dendritic Cells (DCs) has shown long term survival and remission with three severely ill patients in complete or near complete remission of the cancer.